title: Central angiotensin II has catabolic action at white and brown adipose tissue.
abstract: Considerable evidence implicates the renin-angiotensin system (RAS) in the regulation of energy balance. To evaluate the role of the RAS in the central nervous system regulation of energy balance, we used osmotic minipumps to chronically administer angiotensin II (Ang II; icv; 0.7 ng/min for 24 days) to adult male Long-Evans rats, resulting in reduced food intake, body weight gain, and adiposity. The decrease in body weight and adiposity occurred relative to both ad libitum- and pair-fed controls, implying that reduced food intake in and of itself does not underlie all of these effects. Consistent with this, rats administered Ang II had increased whole body heat production and oxygen consumption. Additionally, chronic icv Ang II increased uncoupling protein-1 and β(3)-adrenergic receptor expression in brown adipose tissue and β3-adrenergic receptor expression in white adipose tissue, which is suggestive of enhanced sympathetic activation and thermogenesis. Chronic icv Ang II also increased hypothalamic agouti-related peptide and decreased hypothalamic proopiomelanocortin expression, consistent with a state of energy deficit. Moreover, chronic icv Ang II increased the anorectic corticotrophin- and thyroid-releasing hormones within the hypothalamus. These results suggest that Ang II acts in the brain to promote negative energy balance and that contributing mechanisms include an alteration in the hypothalamic circuits regulating energy balance, a decrease in food intake, an increase in energy expenditure, and an increase in sympathetic activation of brown and white adipose tissue.
authors.affiliation: Department of Physiology and Functional Genomics, College of Medicine, University of Florida, Gainesville, Florida 32611, USA. adekloet@ufl.edu
authors.forename: Annette D
authors.initials: AD
authors.lastname: de Kloet
authors.forename: Eric G
authors.initials: EG
authors.lastname: Krause
authors.forename: Karen A
authors.initials: KA
authors.lastname: Scott
authors.forename: Michelle T
authors.initials: MT
authors.lastname: Foster
authors.forename: James P
authors.initials: JP
authors.lastname: Herman
authors.forename: Randall R
authors.initials: RR
authors.lastname: Sakai
authors.forename: Randy J
authors.initials: RJ
authors.lastname: Seeley
authors.forename: Stephen C
authors.initials: SC
authors.lastname: Woods
mesh_terms: D002001:Adipose Tissue, Brown / Q000187:drug effects* / Q000378:metabolism; D052436:Adipose Tissue, White / Q000187:drug effects* / Q000378:metabolism; D000804:Angiotensin II / Q000008:administration & dosage* / Q000494:pharmacology*; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D001921:Brain / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D004435:Eating / Q000187:drug effects; D015918:Infusion Pumps, Implantable; D057967:Infusions, Intraventricular; D055104:Infusions, Subcutaneous; D008297:Male; D008660:Metabolism / Q000187:drug effects; D051381:Rats; D020318:Rats, Long-Evans
chemical_list: D000804:Angiotensin II